Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K.
O'Connell CL, et al. Among authors: orskov ad.
Clin Cancer Res. 2022 Dec 15;28(24):5306-5316. doi: 10.1158/1078-0432.CCR-22-1810.
Clin Cancer Res. 2022.
PMID: 36222848
Free PMC article.
Clinical Trial.